Fresh delay for $4.3B Roche/Spark deal triggers analyst concerns about gene therapy M&A
Roche CEO Severin Schwan may have prepared the staff at Spark for the fifth delay of its $4.3 billion acquisition — adding a few months of cushion and pushing the deadline as far as April 30, 2020 — but that’s not stopping analysts from becoming seriously concerned.
The FTC’s dragged on investigation, which is holding up the deal, points to something bigger than Spark or Roche, Mani Foroohar of SVB Leerink told Bloomberg. It sends a worrying signal to any buyers looking to make a move in gene therapy M&A.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.